Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Langenhorst JB, van Kesteren C, van Maarseveen EM, Dorlo TPC, Nierkens S, Lindemans CA, de Witte MA, van Rhenen A, Raijmakers R, Bierings M, Kuball J, Huitema ADR, Boelens JJ.

Blood Adv. 2019 Jul 23;3(14):2179-2187. doi: 10.1182/bloodadvances.2018029421.

2.

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Janssen JM, Dorlo TPC, Niewerth D, Wilhelm AJ, Zwaan CM, Beijnen JH, Attarbaschi A, Baruchel A, Fagioli F, Klingebiel T, De Moerloose B, Palumbo G, von Stackelberg A, Kaspers GJL, Huitema ADR.

Clin Pharmacokinet. 2019 Jul 16. doi: 10.1007/s40262-019-00803-y. [Epub ahead of print]

PMID:
31313068
3.

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Palić S, Bhairosing P, Beijnen JH, Dorlo TPC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02507-18. doi: 10.1128/AAC.02507-18. Print 2019 Jul.

4.

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR.

Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6.

PMID:
30617624
5.

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ, van Kesteren C, Huitema ADR.

Clin Pharmacokinet. 2019 May;58(5):627-637. doi: 10.1007/s40262-018-0715-9.

6.

Safe mass drug administration for neglected tropical diseases.

de Souza DK, Dorlo TPC.

Lancet Glob Health. 2018 Oct;6(10):e1054-e1055. doi: 10.1016/S2214-109X(18)30415-7. No abstract available.

7.

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.

Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, Sagaki P, Kimutai R, Were L, Omollo T, Egondi TW, Wasunna M, Alvar J, Dorlo TPC, Alves F.

Clin Infect Dis. 2019 Apr 24;68(9):1530-1538. doi: 10.1093/cid/ciy747.

8.

Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.

Lohy Das J, Rulisa S, de Vries PJ, Mens PF, Kaligirwa N, Agaba S, Tarning J, Karlsson MO, Dorlo TPC.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00518-18. doi: 10.1128/AAC.00518-18. Print 2018 Oct.

9.

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

Kip AE, Wasunna M, Alves F, Schellens JHM, Beijnen JH, Musa AM, Khalil EAG, Dorlo TPC.

Front Cell Infect Microbiol. 2018 Jun 1;8:181. doi: 10.3389/fcimb.2018.00181. eCollection 2018.

10.

Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships.

Kip AE, Castro MDM, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC.

J Antimicrob Chemother. 2018 Aug 1;73(8):2104-2111. doi: 10.1093/jac/dky143.

11.

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

de Vries Schultink AHM, Boekhout AH, Gietema JA, Burylo AM, Dorlo TPC, van Hasselt JGC, Schellens JHM, Huitema ADR.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):431-442. doi: 10.1007/s10928-018-9579-8. Epub 2018 Feb 10.

12.

Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Adriaensen W, Dorlo TPC, Vanham G, Kestens L, Kaye PM, van Griensven J.

Front Immunol. 2018 Jan 12;8:1943. doi: 10.3389/fimmu.2017.01943. eCollection 2017. Review.

13.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG.

J Antimicrob Chemother. 2017 Nov 1;72(11):3131-3140. doi: 10.1093/jac/dkx283.

14.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Kip AE, Schellens JHM, Beijnen JH, Dorlo TPC.

Clin Pharmacokinet. 2018 Feb;57(2):151-176. doi: 10.1007/s40262-017-0570-0. Review.

15.

Letter by Dorlo Regarding Article, "Acupuncture Therapy and Incidence of Depression After Stroke".

Dorlo TPC.

Stroke. 2017 Aug;48(8):e231. doi: 10.1161/STROKEAHA.117.017918. Epub 2017 Jun 29. No abstract available.

PMID:
28663506
16.

Poverty-Related Diseases College: a virtual African-European network to build research capacity.

Dorlo TPC, Fernández C, Troye-Blomberg M, de Vries PJ, Boraschi D, Mbacham WF.

BMJ Glob Health. 2016 Jun 10;1(1):e000032. doi: 10.1136/bmjgh-2016-000032. eCollection 2016.

17.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Kip AE, Kiers KC, Rosing H, Schellens JHM, Beijnen JH, Dorlo TPC.

J Pharm Biomed Anal. 2017 Feb 20;135:160-166. doi: 10.1016/j.jpba.2016.12.012. Epub 2016 Dec 9.

PMID:
28033553
18.

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.

Castro MD, Gomez MA, Kip AE, Cossio A, Ortiz E, Navas A, Dorlo TP, Saravia NG.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02198-16. doi: 10.1128/AAC.02198-16. Print 2017 Mar.

19.

Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review.

Verrest L, Dorlo TPC.

Clin Pharmacokinet. 2017 Jun;56(6):583-606. doi: 10.1007/s40262-016-0467-3. Review.

20.

Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.

Ravinetto R, De Weggheleire A, Dorlo TP, Francque S, Sokkab A, Pouget C, Meessen B, Tabernero P, Newton PN, Lynen L.

Trop Med Int Health. 2016 Dec;21(12):1490-1495. doi: 10.1111/tmi.12784. Epub 2016 Oct 17. No abstract available.

21.

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.

Wasunna M, Njenga S, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TP, Musa B, Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu A, Olobo J, Ellis S, Kimutai R, Wells S, Khalil EA, Strub Wourgaft N, Alves F, Musa A.

PLoS Negl Trop Dis. 2016 Sep 14;10(9):e0004880. doi: 10.1371/journal.pntd.0004880. eCollection 2016 Sep.

22.

Treatment of visceral leishmaniasis: pitfalls and stewardship.

Dorlo TPC, Ostyn BA, Uranw S, Dujardin JC, Boelaert M.

Lancet Infect Dis. 2016 Jul;16(7):777-778. doi: 10.1016/S1473-3099(16)30091-3. No abstract available.

PMID:
27352756
23.

Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis.

Fortin A, Dorlo TP, Hendrickx S, Maes L.

J Antimicrob Chemother. 2016 Jul;71(7):1892-8. doi: 10.1093/jac/dkw089. Epub 2016 Apr 15.

PMID:
27084920
24.

Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.

Dohmen LC, Navas A, Vargas DA, Gregory DJ, Kip A, Dorlo TP, Gomez MA.

J Biol Chem. 2016 Apr 29;291(18):9638-47. doi: 10.1074/jbc.M115.688168. Epub 2016 Feb 22.

25.

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.

Kip AE, Rosing H, Hillebrand MJ, Blesson S, Mengesha B, Diro E, Hailu A, Schellens JH, Beijnen JH, Dorlo TP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2081-9. doi: 10.1128/AAC.02976-15. Print 2016 Apr.

26.

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

Martial LC, Brüggemann RJ, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Muilwijk EW, Verweij PE, Burger DM, Aarnoutse RE, Pickkers P, Dorlo TP.

Clin Pharmacokinet. 2016 Jun;55(6):723-33. doi: 10.1007/s40262-015-0347-2.

27.

Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Roy SL, Atkins JT, Gennuso R, Kofos D, Sriram RR, Dorlo TP, Hayes T, Qvarnstrom Y, Kucerova Z, Guglielmo BJ, Visvesvara GS.

Parasitol Res. 2015 Dec;114(12):4431-9. doi: 10.1007/s00436-015-4684-8. Epub 2015 Sep 2.

28.

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Kip AE, Rosing H, Hillebrand MJ, Castro MM, Gomez MA, Schellens JH, Beijnen JH, Dorlo TP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:57-62. doi: 10.1016/j.jchromb.2015.06.017. Epub 2015 Jun 24.

29.

Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.

Kreeftmeijer-Vegter AR, Dorlo TP, Gruppen MP, de Boer A, de Vries PJ.

Br J Clin Pharmacol. 2015 Aug;80(2):242-52. doi: 10.1111/bcp.12607. Epub 2015 Jun 5.

30.

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP.

Antimicrob Agents Chemother. 2015 Jan;59(1):1-14. doi: 10.1128/AAC.04298-14. Epub 2014 Nov 3. Review.

31.

Different liposomal amphotericin B formulations for visceral leishmaniasis.

Dorlo TP, Balasegaram M.

Lancet Glob Health. 2014 Aug;2(8):e449. doi: 10.1016/S2214-109X(14)70252-9. Epub 2014 Jul 23. No abstract available.

32.

Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.

Ostyn B, Hasker E, Dorlo TP, Rijal S, Sundar S, Dujardin JC, Boelaert M.

PLoS One. 2014 Jun 18;9(6):e100220. doi: 10.1371/journal.pone.0100220. eCollection 2014.

33.

LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.

Blum J, Buffet P, Visser L, Harms G, Bailey MS, Caumes E, Clerinx J, van Thiel PP, Morizot G, Hatz C, Dorlo TP, Lockwood DN.

J Travel Med. 2014 Mar-Apr;21(2):116-29. Review.

34.

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.

Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, EL-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A.

PLoS Negl Trop Dis. 2014 Jan 16;8(1):e2613. doi: 10.1371/journal.pntd.0002613. eCollection 2014.

35.

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure.

Dorlo TP, Rijal S, Ostyn B, de Vries PJ, Singh R, Bhattarai N, Uranw S, Dujardin JC, Boelaert M, Beijnen JH, Huitema AD.

J Infect Dis. 2014 Jul 1;210(1):146-53. Epub 2014 Jan 16.

PMID:
24443541
36.

Reply to Arya and Agarwal.

Dorlo TP, Ostyn BA, Beijnen JH, Boelaert M, Dujardin JC, Rijal S.

Clin Infect Dis. 2013 Sep;57(6):917-8. doi: 10.1093/cid/cit388. Epub 2013 Jun 11. No abstract available.

PMID:
23759350
37.

The global impact of Indian generics on access to health.

Ravinetto RM, Dorlo TP, Caudron JM, Prashanth NS.

Indian J Med Ethics. 2013 Apr-Jun;10(2):118-20. No abstract available.

38.

[Concomitant use of proton pump inhibitors and systemic corticosteroids].

Dorlo TP, Jager NG, Beijnen JH, Schellens JH.

Ned Tijdschr Geneeskd. 2013;157(19):A5540. Dutch.

PMID:
23657097
39.

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC.

Clin Infect Dis. 2013 Jun;56(11):1530-8. doi: 10.1093/cid/cit102. Epub 2013 Feb 20.

PMID:
23425958
40.

Please, let not Western quackery replace traditional medicine in Africa.

Renckens CN, Dorlo TP.

Trop Med Int Health. 2013 Feb;18(2):242-4. doi: 10.1111/tmi.12037. Epub 2012 Dec 10. No abstract available.

41.

Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal.

Uranw S, Ostyn B, Dorlo TP, Hasker E, Dujardin B, Dujardin JC, Rijal S, Boelaert M.

Trop Med Int Health. 2013 Feb;18(2):179-87. doi: 10.1111/tmi.12025. Epub 2012 Nov 30.

42.

Commentary: Substandard medicines are the priority for neglected tropical diseases.

Dorlo TP, Ravinetto RM, Beijnen JH, Boelaert M.

BMJ. 2012 Nov 14;345:e7518. doi: 10.1136/bmj.e7518. No abstract available.

PMID:
23152570
43.

Universal access to quality medicines: prioritisation of a-priori solutions.

Dorlo TP, Boelaert M, Beijnen JH, Ravinetto R.

Lancet Infect Dis. 2012 Nov;12(11):829-30. doi: 10.1016/S1473-3099(12)70259-1. No abstract available.

PMID:
23099080
44.

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ.

J Antimicrob Chemother. 2012 Nov;67(11):2576-97. doi: 10.1093/jac/dks275. Epub 2012 Jul 24. Review.

PMID:
22833634
45.

A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.

Dorlo TP, Eggelte TA, Schoone GJ, de Vries PJ, Beijnen JH.

PLoS Negl Trop Dis. 2012;6(5):e1544. doi: 10.1371/journal.pntd.0001544. Epub 2012 May 29. No abstract available.

46.

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ.

Antimicrob Agents Chemother. 2012 Jul;56(7):3864-72. doi: 10.1128/AAC.00292-12. Epub 2012 May 14.

47.

Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.

Dorlo TP, Balasegaram M, Lima MA, de Vries PJ, Beijnen JH, Huitema AD.

J Antimicrob Chemother. 2012 Aug;67(8):1996-2004. doi: 10.1093/jac/dks164. Epub 2012 May 10.

PMID:
22577099
48.

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.

Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H, Katabira E, Hanpithakpong W, Pakker N, Dorlo TP, Tarning J, Lindegardh N, de Vries PJ, Back D, Khoo S, Merry C.

J Antimicrob Chemother. 2012 May;67(5):1217-23. doi: 10.1093/jac/dkr596. Epub 2012 Feb 8.

49.

Characterization and identification of suspected counterfeit miltefosine capsules.

Dorlo TP, Eggelte TA, de Vries PJ, Beijnen JH.

Analyst. 2012 Mar 7;137(5):1265-74. doi: 10.1039/c2an15641e. Epub 2012 Jan 18.

PMID:
22251969
50.

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.

Dorlo TP, van Thiel PP, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, de Vries PJ.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1436. doi: 10.1371/journal.pntd.0001436. Epub 2011 Dec 13.

Supplemental Content

Loading ...
Support Center